5 completed, 3 unknown, 3 withdrawn, 2 recruiting. 9 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Unknown 3, Withdrawn 2, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow isoquercitrin: new trials by email Literature Review of isoquercitrin trials Research Report on isoquercitrin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Isoquercetin in People With Ovarian Cancer Isoquercetin, Placebo - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 90 | 2026-01-22 | 2026-09-15 |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Kinisoquin™, Placebo - Venous Thromboembolism, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Quercis Pharma AG | 480 | 2025-12-19 | 2026-02-02 |
| Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19 Isoquercetin (IQC-950AN) - COVID-19 | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2022-01-01 | 2025-03-24 | |
| Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19 Hospital standard of care for COVID-19, Isoquercetin - Covid19 | Phase 2 | Unknown | Nepal Health Research Council | 250 | 2021-02-20 | 2021-02-05 |
| Isoquercetin in Sickle Cell Anemia Isoquercetin - Sickle Cell Disease, Sickle Cell-Beta0-Thalassemia | Phase 2 | Withdrawn | Jeffrey Zwicker, MD | 2020-12-01 | 2021-01-11 | |
| Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease Isoquercetin, Placebo - Sickle Cell Disease | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 46 | 2020-11-02 | 2024-01-02 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial Sunitinib, Isoquercetin, Placebo - Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | Unknown | Consorzio Oncotech | 104 | 2016-11-01 | 2017-01-18 |
| Impact of isoQUercetin and Aspirin on Platelet Function Vehicle control, Isoquercetin, Aspirin - Cardiovascular Disease | Not applicable | Withdrawn | University of Reading | 2016-08-01 | 2016-11-29 | |
| Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial Immediate release sodium nitrite, Isoquercetin, placebos - Chronic Kidney Disease | Phase 2 | Completed | Tulane University | 70 | 2016-03-01 | 2021-04-20 |
| Cancer Associated Thrombosis and Isoquercetin (CATIQ) Isoquercetin - Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer | Phase 2 / Phase 3 | Completed | Jeffrey Zwicker, MD | 64 | 2015-01-01 | 2021-03-03 |
| Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States isoquercetin or quercetin - Healthy | Early Phase 1 | Completed | Beth Israel Deaconess Medical Center | 38 | 2012-05-01 | 2020-10-12 |
| Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) Quercetin, Placebo - Flushing | Phase 4 | Completed | University of Pennsylvania | 17 | 2009-02-01 | 2015-03-05 |
COVID-19 (3) · Anemia, Sickle Cell (2) · Venous Thrombosis (2) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Cardiovascular Diseases (1) · Fatigue (1) · Flushing (1) · Inflammation (1) · Kidney Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Pulmonary Embolism (1) · Renal Insufficiency, Chronic (1) · Thromboembolism (1)
Jeffrey Zwicker, MD (2) · AB Science (1) · Beth Israel Deaconess Medical Center (1) · Consorzio Oncotech (1) · Institut de Recherches Cliniques de Montreal (1) · Memorial Sloan Kettering Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Nepal Health Research Council (1) · Quercis Pharma AG (1) · Tulane University (1) · University of Pennsylvania (1) · University of Reading (1)
United States (7) · France (1) · Italy (1) · United Kingdom (1)
Jeffrey Zwicker, MD (4) · Arun S Shet, M.D. (1) · Giuseppe Di Lorenzo, MD (1) · Jing Chen, MD (1) · Julie A Lovegrove, BSc PhD RNutr (1) · Pascal Chanez, MD (1) · Richard L. Dunbar, MD (1)
PMID 21277078, PMID 22045104, PMID 23747347, PMID 28097231, PMID 30652973, PMID 33023894, PMID 36048877, PMID 37117213, PMID 37916745, PMID 38157227
2015 (1), U54GM104940 (1)